Caris Life Sciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
CAI$24.43-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| (amounts in thousands) | Nine Months Ended September 30, | |
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net income (loss) | $14,103 | $(150,045) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 18,209 | 18,324 |
| Stock-based compensation expense | 56,589 | 56,639 |
| Non-cash operating lease expense | 4,321 | 4,323 |
| Amortization of debt discounts | 3,234 | 12,163 |
| Changes in fair value of financial instruments | — | 52,284 |
| Loss on debt extinguishment | 25,232 | 17,930 |
| Other | 3,074 | 788 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (21,182) | 61,232 |
| Supplies | (78,467) | (11,144) |
| Prepaid expenses and other current assets | (5,711) | (4,805) |
| Other assets | (409) | (326) |
| Accounts payable | 18,042 | (1,196) |
| Accrued expenses and other liabilities | 2,072 | (17,792) |
| Net cash provided by operating activities | 39,107 | 38,375 |
| Cash flows from investing activities | ||
| Sale of marketable securities | 1,874 | — |
| Purchases of marketable securities | (101,991) | — |
| Capitalized software and purchases of property and equipment | (49,887) | (11,170) |
| Net cash used in investing activities | (150,004) | (11,170) |
| Cash flows from financing activities | ||
| Payments made on finance lease obligations | (125) | (67) |
| Proceeds from exercise of stock options | 26,054 | 3,775 |
| Payment of taxes withheld from net settlement of exercised options and vested RSUs | (5,426) | (18,218) |
| Payment of deferred offering costs | — | (7,710) |
| Repurchase of common stock | (31,371) | (22) |
| Repayment of the 2023 term loan | (406,307) | — |
| Proceeds from the 2026 term loan, net of issuance costs | 393,500 | — |
| Payment of third-party debt issuance costs | (1,107) | — |
| Proceeds from share purchases under employee stock purchase plan | 2,937 | — |
| Issuance of Series E Preferred Stock, net of issuance costs | — | 87,637 |
| Issuance of Series F Preferred Stock, net of issuance costs | — | 33,601 |
| Issuance of the 2025 Convertible Notes, net of issuance costs | — | 27,865 |
| Issuance of the 2025 Warrants | — | 10,270 |
| Payments of the 2023 term loan amendment fee | — | (4,000) |
| Proceeds from initial public offering, net of underwriting discounts and commissions | — | 528,459 |
| Net cash provided by (used in) financing activities | (21,845) | 661,590 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (149) | 159 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (132,891) | 688,954 |
| Cash, cash equivalents, and restricted cash at beginning of period | 800,042 | 68,028 |
| Cash, cash equivalents, and restricted cash at end of period | $667,151 | $756,982 |
| Reconciliation of cash, cash equivalents, and restricted cash | ||
| Cash, cash equivalents, and restricted cash | $665,321 | $754,739 |
| Restricted cash included in other long-term assets | 1,830 | 2,243 |
| Total cash, cash equivalents, and restricted cash | $667,151 | $756,982 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.